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Background
Atezolizumab (anti-PD-L1) has demonstrated robust
clinical activity in UBC [1]. Elevated PD-L1 expression
on tumor-infiltrating immune cells (IC) is associated
with increased clinical efficacy; however, the contribu-
tion of other immune biomarkers is unknown. In this
study, we explored tumor-based and circulating biomar-
kers and their correlation with clinical benefit in atezoli-
zumab-treated patients with UBC.
Methods
Patients from the UBC cohort (n = 92) of the Phase Ia ate-
zolizumab trial PCD4989g (NCT01375842) served as
source population for tumor specimens, plasma and
PBMC. Baseline tumor PD-L1 expression was assessed by
immunohistochemistry using the SP142 antibody assay
optimized to detect PD-L1 on both tumor cells (TC) and
IC. RNA gene expression on tumor and PBMC samples
was interrogated with a NanoString panel of 800 immune
and cancer genes. Sequential blood draws assessed
dynamic changes in circulating immune biomarkers in
plasma (RBM, Multi-Analyte Platform). Correlation
between biomarker expression and 6-month progression-
free survival (PFS; as a measure of clinical benefit) was
assessed.
Results
Baseline gene expression in tumors revealed an effector
T cell signature (including CD8A, GZMA, IFNG) and NK
gene signature (NKG2 family members) associated with
clinical benefit. In contrast, disease progression was asso-
ciated with either a concomitant presence of the immune
signature and an opposing stromal signature (PDPN,
COL5A1, etc) or the absence of both signatures. Expres-
sion of T cell effector and immune checkpoint genes
(CTLA4, PD-1, TIGIT, LAG3) correlated with PD-L1
expression on IC but not TC. Increased expression of
myeloid-derived cytokines (IL-6 and IL-8) in the plasma
was associated with lack of clinical benefit. Moreover,
on-treatment sampling revealed an increased plasma
HCG, CA15-3 and TIMP-1 to be correlated with disease
progression. Immune biomarkers associated with PBMC,
as well as tumor biomarkers associated with various
tumor subtypes, will also be discussed.
Conclusions
Our findings indicate that clinical benefit (as defined by
6-month PFS) from atezolizumab is influenced by a pre-
existing CD8+ effector T cell and NK cytolytic gene sig-
nature in the tumor, which correlated with IC PD-L1
expression. Increased stromal and myeloid-derived cyto-
kine expression in tumor and plasma, respectively, were
associated with lack of clinical benefit, underscoring the
complex interplay among immunological components in
UBC. These components may be conceivable targets to
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